| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -53,795 | -36,798 |
| Depreciation | 466 | 311 |
| Stock-based compensation | 11,114 | 7,524 |
| Amortization of premiums on investment securities, net | 2,741 | 1,974 |
| Non-cash lease expense | -13 | -6 |
| Deferred financing costs | 427 | 427 |
| Prepaid expense and other assets | 496 | 955 |
| Accounts payable and other liabilities | 2,646 | 241 |
| Net cash used in operating activities | -42,392 | -31,230 |
| Purchases of investment securities | 204,155 | 126,080 |
| Proceeds from maturities of investment securities | 238,810 | 154,225 |
| Purchases of property and equipment | 159 | 159 |
| Net cash provided by investing activities | 34,496 | 27,986 |
| Issuance of common stock through employee stock purchase plan | 361 | 361 |
| Proceeds from the exercise of stock options | 60 | 23 |
| Net cash provided by financing activities | 421 | 384 |
| Net (decrease) increase in cash and cash equivalents | -7,475 | -2,860 |
| Cash and cash equivalents at beginning of period | 22,563 | - |
| Cash and cash equivalents at end of period | 15,088 | - |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)